Published in Am J Hypertens on May 01, 2007
Arginase and vascular aging. J Appl Physiol (1985) (2008) 1.33
Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol (2009) 1.28
Cardiovascular risk factors for incident hypertension in the prehypertensive population. Epidemiol Health (2010) 0.85
Prehypertension. To treat, or not to treat: that is the question. Am J Hypertens (2007) 0.78
Microalbuminuria in untreated prehypertension and hypertension without diabetes. Int J Clin Exp Med (2014) 0.75
Should Pre-hypertension Be Treated? Curr Hypertens Rep (2017) 0.75
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA (2011) 8.83
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension (2005) 5.05
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil (2003) 4.25
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med (2002) 3.61
Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension (2007) 3.57
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens (2002) 3.43
Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension (2006) 3.42
Telomere length and possible link to X chromosome. Lancet (2004) 3.36
Prognosis among healthy individuals discharged with a primary diagnosis of syncope. J Am Coll Cardiol (2012) 3.33
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell (2013) 3.27
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncol (2006) 2.88
Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA (2012) 2.85
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens (2009) 2.71
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens (2003) 2.71
The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ (2012) 2.65
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol (2013) 2.61
Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation (2006) 2.58
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension (2005) 2.54
Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol (2011) 2.50
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens (2005) 2.47
Ambulatory blood pressure and mortality: a population-based study. Hypertension (2005) 2.34
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33